CAN1012 in Pre-Malignant DCIS and LCIS

Starting soon · Phase 1

Conditions studied: Ductal Carcinoma in Situ, Lobular Carcinoma in Situ

In brief

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

Key facts

Study ID: NCT07408856
Run by: Providence Health & Services
People needed: 24
Starts: 2026-08-01
Expected to finish: 2035-05-01
Last updated by the study team: 2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female patients with DCIS or LCIS found on core biopsy.
Tumor types allowed:
Biopsy-identified DCIS or LCIS comprising a single lesion ≥ 1 cm and ≤ 5 cm in size by imaging (mammogram or MRI or ultrasound (US)) without evidence of invasive disease on the biopsy and US negative for suspicious ipsilateral lymph nodes.
Age 18 years or above with ability to give informed consent, comply with the protocol, and sign a study-specific consent document.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 deemed suitable by investigator or designee for requirements of study.
Laboratory values within 72 hours of Day 0:
WBC ≥ 2.0 K/µL, ANC ≥ 1.0 K/µL
Hgb ≥ 10 g/dL
Platelets ≥ 100,000 K/µL
Creatinine Clearance (using Cockcroft-Gault) ≥ 60.
AST/ALT ≤ 2.5 x ULN
Total bilirubin ≤ 3 x ULN, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Negative pregnancy test for people of childbearing potential (bHCG urine or serum)
Patients and their partners who are capable of conceiving must agree to use effective methods of contraception (non-hormonal only) during the course of treatment and for 165 days after last dose of CAN1012.

You may not qualify if…

Any serious underlying medical or psychiatric condition that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study procedures, completion, or evaluation.
Need for corticosteroids ≥ 10mg prednisone daily equivalent; inhaled steroids are acceptable.
Need for hormonal contraception including oral contraceptives, implant, injectable depots, vaginal rings, skin patches, and the progestin IUD; or any medication that is a sensitive substrate of the major CYPs.
History of or current active autoimmune diseases which, in the judgment of the investigator, pose an active and significant risk. Vitiligo, lichen planus or lichenoid inflammation, and adequately controlled endocrine deficiencies such as hypothyroidism/hyperthyroidism are not exclusionary.
Previous history of bone marrow transplantation or oral Graft Versus Host Disease (GVHD).
Has an active infection requiring systemic therapy. Investigator may allow if deemed not clinically significant.
Has active or uncontrolled Hepatitis B, Hepatitis C, or HIV with AIDS (acquired immunodeficiency syndrome)- defined opportunistic infection.
Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known history of Hepatitis C virus (defined as HCV RNA) infection. Testing for Hepatitis B and Hepatitis C is not required unless mandated by local health authority.
Has a baseline electrocardiogram (ECG) with a prolonged QTc interval > 480 msec. Medications which have a known and clinically significant risk of QT prolongation may be allowed per investigator discretion.
Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation, and in the judgment of the investigator still pose an active risk.

Where it is running

Providence Portland Cancer Institute - Franz Clinic — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.